Abstract
BackgroundThis retrospective cohort study aimed to evaluate the clinical outcomes of H101 combined with chemotherapy for advanced gastric carcinoma (GC) patients.MethodsThe advanced GC patients, who were treated with H101 and/or chemotherapy, were enrolled and divided into three groups according to treatment method. The clinical characteristics of patients, clinical short-term and long-term outcomes, followed up, and complication were analyzed.ResultsA total of 95 patients (30 patients in group A were treated with H101, 33 in group B patients were treated with chemotherapy, 32 patients in group C were treated with H101 combined with chemotherapy) were retrospectively reviewed. The disease control rate (DCR) and overall response rate (ORR) were significantly greater in group C (81.3% and 50.0%) than in groups A (63.3% and 30.0%) and B (66.7% and 33.3%, all p < 0.05). The 1- and 2-year survival rates and progression-free survival were significantly greater in group C than in groups A and B (all p < 0.05). There was no significant difference in complication among the three groups. At dose levels of 0.5 × 1012 vp/day, 1.0 × 1012 vp/day, and 1.5 × 1012 vp/day, complications were not increased as increased of dose.ConclusionsH101 combined with chemotherapy may be a potential therapeutic option for patients with advanced GC, and prospective studies with proper assessment of toxicity will be needed in the future.
Highlights
Gastric carcinoma (GC) is one of the most common malignant tumors in digestive system
All patients were at stage III/IV GC and not suitable for surgical resection: 30 cases were treated with H101, including 17 males and 13 females, aged from 47 to 78 years; 33 cases received chemotherapy, including 19 males and 14 females, aged 45–76 years; and 32 cases were treated with H101 combined with chemotherapy, including 20 males and 12 females, aged 48 to 80 years
The disease control rate (DCR) and overall response rate (ORR) were both higher in patients treated with H101 combined with chemotherapy than in those treated with H101 alone or chemotherapy alone
Summary
Gastric carcinoma (GC) is one of the most common malignant tumors in digestive system. Immunotherapy needs to select appropriate population according to specific molecular markers, and some GC patients have good clinical efficacy after initial immunotherapy, but may have recurrence [7] These drawbacks indicate the new strategies for advanced GC are urgently needed. Oncolytic virus (OV) therapy is poised to be one of the leading treatments for cancer, due to OVs offering the attractive therapeutic combination of tumor-specific cell lysis together with immune stimulation to kill cancer cells, leaving nonmalignant cells unharmed [8]. This retrospective cohort study aimed to evaluate the clinical outcomes of H101 combined with chemotherapy for advanced gastric carcinoma (GC) patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
